The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MRD Focus: why measurable residual disease testing is the future
Measurable residual disease (MRD) testing has the potential to transform the landscape of disease prognosis and clinical decision-making in the field of hemato-oncology.
MRD describes the small number of cancer cells that still remain in patients that routine morphological detection does not detect. MRD testing is emerging as a benchmark prognostic indicator, which could potentially be used to improve patient outcomes.
MRD Focus is the new platform delivering the latest MRD updates to you, including a range of expert interviews, panel discussions, podcasts and interactive e-learning content.
Discover the latest advancements now at https://www.vjhemonc.com/field/mrd/
